Geron (GERN)
(Delayed Data from NSDQ)
$3.58 USD
+0.08 (2.29%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $3.57 -0.01 (-0.28%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GERN 3.58 +0.08(2.29%)
Will GERN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GERN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GERN
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Company News for Mar 18, 2024
GERN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up
Implied Volatility Surging for Geron (GERN) Stock Options
Geron (GERN) Upgraded to Buy: Here's Why
Other News for GERN
3 Red-Hot Biotech Rockets Blasting Off in 2024
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Argan Reports Upbeat Earnings, Joins Coupang And Other Big Stocks Moving Higher On Friday
Jim Cramer: This Tech Stock Is 'Great,' Archer Aviation Is 'Too Speculative For Me'
Buy Rating Affirmed for Geron Following Insightful Leadership Discussion and Promising Drug Development Progress